Clinical Trial Update: A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis [Phase 2]

View source ↗

Summary

Phase 2 trial update of single-dose intranasal GSK256066 for allergic rhinitis shows completed status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rhinitis Allergic Seasonal

Drugs mentioned

• GSK256066

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rhinitis, Allergic, Seasonal | Phase 2 | Status: COMPLETED | Results posted: 2017-08-21